Plasma was collected before IFN-γ, 48–72 hours after IFN-γ, 4 weeks after IFN-γ monotherapy before DLI, 4 weeks after DLI, and at subsequent times associated with clinical events (GVHD, CR, or disease progression). The gene discussed is IFNG; the disease is graft versus host disease.